CN111065403B - 细胞杀伤剂 - Google Patents

细胞杀伤剂 Download PDF

Info

Publication number
CN111065403B
CN111065403B CN201880054701.XA CN201880054701A CN111065403B CN 111065403 B CN111065403 B CN 111065403B CN 201880054701 A CN201880054701 A CN 201880054701A CN 111065403 B CN111065403 B CN 111065403B
Authority
CN
China
Prior art keywords
peptide
cngb3
amino acid
cells
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880054701.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111065403A (zh
Inventor
杉原一广
金山尚裕
小野寺雄一郎
柴田俊章
福田道子
野中元裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
Original Assignee
Fujita Health University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University filed Critical Fujita Health University
Publication of CN111065403A publication Critical patent/CN111065403A/zh
Application granted granted Critical
Publication of CN111065403B publication Critical patent/CN111065403B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880054701.XA 2017-08-24 2018-08-23 细胞杀伤剂 Active CN111065403B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-161556 2017-08-24
JP2017161556A JP6613499B2 (ja) 2017-08-24 2017-08-24 細胞殺傷剤
PCT/JP2018/031136 WO2019039540A1 (ja) 2017-08-24 2018-08-23 細胞殺傷剤

Publications (2)

Publication Number Publication Date
CN111065403A CN111065403A (zh) 2020-04-24
CN111065403B true CN111065403B (zh) 2023-09-26

Family

ID=65438932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880054701.XA Active CN111065403B (zh) 2017-08-24 2018-08-23 细胞杀伤剂

Country Status (9)

Country Link
US (2) US11357819B2 (enExample)
EP (1) EP3738601A4 (enExample)
JP (1) JP6613499B2 (enExample)
KR (1) KR102427844B1 (enExample)
CN (1) CN111065403B (enExample)
AU (1) AU2018322305B2 (enExample)
CA (1) CA3073392C (enExample)
SG (1) SG11202001484QA (enExample)
WO (1) WO2019039540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
WO2019138944A1 (ja) 2018-01-09 2019-07-18 学校法人藤田学園 細胞殺傷剤
JP2024517518A (ja) * 2021-05-07 2024-04-23 ツインピグ バイオラブ インコーポレイテッド マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用
CN115725968A (zh) * 2022-11-18 2023-03-03 东莞宜安科技股份有限公司 一种生物医用钛合金表面的复合涂层及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102905534A (zh) * 2010-04-06 2013-01-30 约翰·W·霍拉迪 治疗癌症的方法
WO2015041019A1 (ja) * 2013-09-18 2015-03-26 国立大学法人 京都大学 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2634934A1 (en) * 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
EP2414389A1 (en) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides
WO2011027312A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS
JP6184101B2 (ja) * 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート アネキシン１結合化合物に関する方法および組成物
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US9783576B2 (en) * 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
US10338068B2 (en) * 2013-07-08 2019-07-02 The Trustees Of Columbia University In The City Of New York Selection of biological objects
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
RU2571551C1 (ru) 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017161556A (ja) 2017-06-27 2017-09-14 パイオニア株式会社 位置認識装置、制御方法、プログラム、及び記憶媒体
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102905534A (zh) * 2010-04-06 2013-01-30 约翰·W·霍拉迪 治疗癌症的方法
WO2015041019A1 (ja) * 2013-09-18 2015-03-26 国立大学法人 京都大学 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Development of pro-apoptotic peptides as potential therapy for peritoneal endometriosis;K. Sugihara, et al.;《NATURE COMMUNICATIONS》;20140722;1-9 *

Also Published As

Publication number Publication date
AU2018322305B2 (en) 2021-05-20
CA3073392A1 (en) 2019-02-28
WO2019039540A1 (ja) 2019-02-28
JP2019038772A (ja) 2019-03-14
KR20200031670A (ko) 2020-03-24
JP6613499B2 (ja) 2019-12-04
CN111065403A (zh) 2020-04-24
SG11202001484QA (en) 2020-03-30
KR102427844B1 (ko) 2022-07-29
US20200289608A1 (en) 2020-09-17
EP3738601A4 (en) 2021-06-16
CA3073392C (en) 2023-02-21
EP3738601A1 (en) 2020-11-18
AU2018322305A1 (en) 2020-03-05
US20220280596A1 (en) 2022-09-08
US11357819B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
Gribar et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis
US20220280596A1 (en) Cytocidal agent
Yuan et al. The human milk-derived peptide drives rapid regulation of macrophage inflammation responses in the neonatal intestine
US20230391868A1 (en) Compositions for and methods of treating cancer
CA3162518A1 (en) Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
KR20130130562A (ko) 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도
Troncoso et al. Disrupted brain angiogenesis and blood–brain barrier function underlie cognitive deficits in offspring of preeclampsia‐like pregnancies
CN113209313A (zh) Tgfbr2在制备卵巢功能保护药物方面中的应用
HK40023962A (zh) 细胞杀伤剂
US10751324B2 (en) Treatment of TNF- alpha cytotoxicity
CA3087744C (en) CYTOCIDAL AGENT
ES2321822T3 (es) Antagonistas de los receptores de eg-vegf/procineticina 2.
Saha et al. Autophagy Increases Occludin Levels to Enhance Intestinal Paracellular Tight Junction Barrier
HK40032209A (en) Cytocide
JP7227589B2 (ja) 疾患の発症に関する診断のための情報を提供する方法
A Albati Characterisation of novel Markers role in Senescence and targeting them to eliminate senescent cells
Falkenberg The role of CCDC103 in the cytoskeletal dynamics, metabolic regulation, and functional maturation of zebrafish and human neutrophils
Han et al. Amisodin alleviates TDP-43-associated ALS pathology by inhibiting the trimeric SOD1
Hackam et al. Reciprocal Expression and Signaling of TLR4
Deng et al. GOLGA2/GM130 is a Novel Target for Neuroprotection Therapy in Intracerebral Hemorrhage
CN116745619A (zh) 靶向pacs1的化合物及其使用方法
Ellis et al. BECLIN1 is essential for intestinal homeostasis involving autophagy-independent mechanisms through its function in endocytic trafficking

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40023962

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant